Aptose Biosciences (TSE:APS) (NASDAQ:APTO) is scheduled to post its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Aptose Biosciences to post earnings of C($0.19) per share for the quarter.
Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported C($0.19) EPS for the quarter, topping analysts’ consensus estimates of C($0.23) by C$0.04.
APS stock traded up C$0.02 during trading on Tuesday, reaching C$3.25. 7,091 shares of the stock were exchanged, compared to its average volume of 24,685. The company has a quick ratio of 5.72, a current ratio of 5.93 and a debt-to-equity ratio of 11.72. The stock has a 50 day simple moving average of C$3.34. Aptose Biosciences has a 1 year low of C$2.08 and a 1 year high of C$4.19. The stock has a market cap of $174.07 million and a price-to-earnings ratio of -4.23.
Separately, Roth Capital restated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.